Leon O. Moulder Jr.
Leon O. Moulder Jr.'s purchase track record
How the stock did after each of Leon O. Moulder Jr.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/18/2026 | ZBIO | $1.01M | +80.4% | pending | — |
| 4/28/2026 | ZBIO | $1.07M | +79.3% | pending | — |
| 3/30/2026 | ZBIO | $1.02M | +40.2% | +51.2% | +21.1% |
| 2/2/2026 | ZBIO | $1.02M | +18.8% | +73.1% | +8.9% |
| 1/7/2026 | ZBIO | $1.64M | +26.4% | +74.2% | +8.1% |
| 10/7/2025 | ZBIO | $770K | -27.1% | +7.8% | -1.5% |
| 2/18/2025 | ZBIO | $167K | +72.6% | +138.3% | +4.6% |
| 12/3/2024 | ZBIO | $718K | -35.4% | -11.3% | -1.3% |
| 11/18/2024 | ZBIO | $149K | -55.9% | -27.0% | +1.2% |
| 9/18/2024 | ZBIO | $361K | -48.5% | -53.9% | +1.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ZBIO releases Phase 3 Obexelimab data, plans MS trial presentations. The company released new Phase 3 results for its Obexelimab program in IgG4‑related disease, which were presented at a recent international symposium. The data release coincided with a 5.1% share decline. Zenas also announced upcoming virtual presentations of Orelabrutinib data for multiple sclerosis at MSToronto2026 and a broader R&D webcast. Analyst HC Wainwright kept its $44 price target, reinforcing its view on the stock.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
DNTH Highlighted by Benzinga and Announces Nasdaq Inducement Grants. Dianthus Therapeutics was named one of the top three health‑care stocks in a recent Benzinga feature that looks at companies that could help improve a portfolio this quarter. The company also disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4), a filing that relates to compliance with Nasdaq’s listing standards. Both items raise the company’s public profile and address regulatory requirements.
Transaction History
| ZLAB | ▲ Buy | Grant | 22,371 | $0 | 6/17/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 60,000 | $1.0M | 5/18/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 35,000 | $617K | 4/29/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 25,000 | $451K | 4/28/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 34,000 | $657K | 3/31/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 20,000 | $365K | 3/30/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 57,000 | $1.0M | 2/2/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 20,000 | $331K | 1/9/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 30,000 | $489K | 1/8/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 50,000 | $819K | 1/7/2026 | View on chart |
| ZBIO | ▲ Buy | Open Market | 36,928 | $770K | 10/7/2025 | View on chart |
| ZLAB | ▲ Buy | Grant | 10,831 | $0 | 6/18/2025 | View on chart |
| ZBIO | ▲ Buy | Open Market | 25,000 | $167K | 2/18/2025 | View on chart |
| ZBIO | ▲ Buy | Open Market | 45,000 | $449K | 12/4/2024 | View on chart |
| ZBIO | ▲ Buy | Open Market | 25,000 | $269K | 12/3/2024 | View on chart |
| ZBIO | ▲ Buy | Open Market | 2,500 | $36K | 11/19/2024 | View on chart |
| ZBIO | ▲ Buy | Open Market | 7,500 | $113K | 11/18/2024 | View on chart |
| ZBIO | ▲ Buy | Open Market | 2,367 | $42K | 9/20/2024 | View on chart |
| ZBIO | ▲ Buy | Open Market | 2,633 | $50K | 9/20/2024 | View on chart |
| ZBIO | ▲ Buy | Open Market | 5,000 | $89K | 9/19/2024 | View on chart |
| ZBIO | ▲ Buy | Open Market | 10,000 | $179K | 9/18/2024 | View on chart |
| ZBIO | ▼ Sell | Other | 372,017 | — | 9/16/2024 | View on chart |
| ZBIO | ▼ Sell | Other | 48,254 | — | 9/16/2024 | View on chart |
| ZBIO | ▼ Sell | Other | 164,523 | — | 9/16/2024 | View on chart |
| ZBIO | ▼ Sell | Other | 108,381 | — | 9/16/2024 | View on chart |
| ZLAB | ▲ Buy | Grant | 21,253 | $0 | 6/18/2024 | View on chart |
| DNTH | ▲ Buy | Grant | 166,667 | $2.0M | 1/22/2024 | View on chart |
| ZLAB | ▲ Buy | Grant | 18,903 | $500K | 6/29/2023 | View on chart |
| ZLAB | ▲ Buy | Grant | 7,763 | $0 | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Zai Lab Releases Q2 2026 Earnings and Call Transcript
Zai Lab has published its second-quarter 2026 financial results along with the full earnings call transcript. This update provides investors with the latest details on the company's performance and strategic outlook. The stock is currently trading within its 52-week range, with analysts maintaining a wide target price spread.
Zai Lab Releases Q2 2026 Earnings and Call Transcript. Zai Lab has published its second-quarter 2026 financial results along with the full earnings call transcript. This update provides investors with the latest details on the company's performance and strategic outlook. The stock is currently trading within its 52-week range, with analysts maintaining a wide target price spread.